Immune cell therapy tested for early lung cancer safety
NCT ID NCT07498439
First seen Mar 31, 2026 · Last updated May 01, 2026 · Updated 3 times
Summary
This early-stage study tests the safety of a therapy using a patient's own immune cells, called tumor-infiltrating lymphocytes (TILs), to treat early-stage non-small cell lung cancer. The study will enroll 50 people with multiple lung nodules that have not gone away after a year. The main goal is to see if the treatment causes any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY EARLY-STAGE NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.